Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience.
Ontology highlight
ABSTRACT: Dramatic advances in our understanding of the molecular pathophysiology of cancer, along with a rapidly expanding portfolio of molecular targeted drugs, have led to a paradigm shift toward personalized, biomarker-driven cancer treatment. Here, we report the 2-year experience of the Comprehensive Cancer Center Freiburg Molecular Tumor Board (MTB), one of the first interdisciplinary molecular tumor conferences established in Europe. The role of the MTB is to recommend personalized therapy for patients with cancer beyond standard-of-care treatment. This retrospective case series includes 198 patients discussed from March 2015 through February 2017. The MTB guided individual molecular diagnostics, assessed evidence of actionability of molecular alterations, and provided therapy recommendations
SUBMITTER: Hoefflin R
PROVIDER: S-EPMC7446498 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
ACCESS DATA